Related references
Note: Only part of the references are listed.Pooled safety analysis of zanubrutinib monotherapy in patients with B-cell malignancies
Constantine S. Tam et al.
BLOOD ADVANCES (2022)
Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Kerry A. Rogers et al.
HAEMATOLOGICA (2021)
Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies
Richard R. Furman et al.
LEUKEMIA (2021)
Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia: Results of the First Randomized Phase III Trial
John C. Byrd et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Rationale for once-daily or twice-daily dosing of zanubrutinib in patients with mantle cell lymphoma
Ying C. Ou et al.
LEUKEMIA & LYMPHOMA (2021)
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstrom macroglobulinemia: the ASPEN study
Constantine S. Tam et al.
BLOOD (2020)
Discovery of Zanubrutinib (BGB-3111), a Novel, Potent, and Selective Covalent Inhibitor of Bruton's Tyrosine Kinase
Yunhang Guo et al.
JOURNAL OF MEDICINAL CHEMISTRY (2019)
BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression
Paul J. Hampel et al.
BLOOD (2019)
How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia
Deborah M. Stephens et al.
BLOOD (2019)
Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
Farrukh T. Awan et al.
BLOOD ADVANCES (2019)
Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma
Susan O'Brien et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis
Anthony R. Mato et al.
HAEMATOLOGICA (2018)
Potency and Selectivity of BTK Inhibitors in Clinical Development for B-Cell Malignancies
Allard Kaptein et al.
BLOOD (2018)
Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile
Tjeerd Barf et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2017)
PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment
D. Jones et al.
LEUKEMIA (2017)
Using high-sensitivity sequencing for the detection of mutations in BTK and PLCγ2 genes in cellular and cell-free DNA and correlation with progression in patients treated with BTK inhibitors
Adam Albitar et al.
Oncotarget (2017)
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
CCND1 mutations increase protein stability and promote ibrutinib resistance in mantle cell lymphoma
Atish Mohanty et al.
ONCOTARGET (2016)
Three-year follow-up of treatment-naive and previously treated patients with CLL and SLL receiving single-agent ibrutinib
John C. Byrd et al.
BLOOD (2015)
Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia
Kami J. Maddocks et al.
JAMA ONCOLOGY (2015)
Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)
Jennifer A. Woyach et al.
BLOOD (2014)
Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Response assessment in Waldenstrom macroglobulinaemia: update from the VIth International Workshop
Roger G. Owen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
John C. Byrd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
B cell receptor signaling in chronic lymphocytic leukemia
Jan A. Burger et al.
TRENDS IN IMMUNOLOGY (2013)
Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia
Bruce D. Cheson et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
Lee A. Honigberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)